NCT03619902Phase 2Completed

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis

Study sponsor: Vanda Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2021-01-20Actual
Enrollment · participants8Actual
Source updated2025-09-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.